Materials and Methods We performed a prospective study of a SLE pregnant cohort. All patients were evaluated and followed with the same clinical protocol in a multidisciplinary care unit (internal medicine, gynecology, hematology, nephrology) from January 2008 to December 2018. Clinical and laboratory data were collected in a preformed clinical record registry.

Results Seventy pregnancy (67-women) with a medium age of 26 (16–41) years old were included. Before pregnancy SLE involvement was: cutaneous (75%), joint (65%), hematological (41%) and renal (40%) (Type -WHO- I:2/II:9/III:3/ IV.5/9). Eleven patients had carried out a preconception counselling. Median time between SLE onset and pregnancy was 6 (1–25) years. At the beginning of the follow-up, disease was active in 15,7% and status of antibodies was: persistently positive antiphospholipid: 32.8%, anti-SSA/Ro: 24%, anti-SSB/La: 10%. Mycophenolate, enalapril and warfarin treatment was suspended at the first visit. During pregnancy treatment included: corticosteroids (63%), azathioprine (43%), hydroxychloroquine (97%), low-molecular-weight heparin (48%) and low-dose aspirin (74%). Thirty-two patients had SLE-flare and 19 (27%) preeclampsia. Pre-term delivery (PD) was 42.9%. SLE-flare during pregnancy was associated with PD (p=0.00) and preeclampsia (p=0.04). Lupus nephritis (regardless of activity) was associated with PD (p =0.00) and preeclampsia (p =0.03). Forty-five women had a cesarean section and 37% of them were admitted with preterm labor. Median gestational age at birth was 37±5 weeks and median birth weight was 2770 (710–4315) gr. There were two fetal deaths, two abortions and no maternal deaths.

Conclusion We present the first report of pregnancy outcomes of lupus patients in Uruguay. We highlight the low rate of complications, fetal and maternal death. It is possible that close, protocolized and multidisciplinary follow-up have a positive influence in these good results.

Patients with SLE had more frequent C allele compared to controls (20% vs 13%, P = 0.041).

However, the allele and genotype frequencies did not show any difference in patients with nephritis in comparison to those without nephritis.

Conclusion The rs729302 C allele and AC genotype can be considered as risk factors for the development of SLE in Algerian patients.

Background A single nucleotide polymorphism in NCF1 (NCF1-339, rs201802880), encoding NADPH oxidase complex 2 subunit p47^^phox, reducing production of reactive oxygen species (ROS) is highly associated with development of systemic lupus erythematosus (SLE). However, the effect of NCF1-339 genotype on SLE regarding pathogenetic processes or comorbidities has not been investigated.

Methods NCF1-339 genotyped SLE subjects from four Swedish university hospitals were investigated regarding neutrophil ROS production (n=31), neutrophil extracellular traps (NETs) (n=31), serum interferon (n=141), autoantibody profiles (n=305) and clinical phenotypes (n=1087).

Results Compared to SLE patients with normal-ROS NCF1-339 genotypes, neutrophils from patients with low-ROS genotypes displayed impaired NET-formation and increased dependence on mitochondrial ROS for canonical NET-release. An increased frequency of low-ROS patients had high serum interferon activity. Patients with low-ROS genotypes had an increased frequency of positivity for antiphospholipid antibodies anti-β2 glycoprotein I and anti-cardiolipin, related to the severe comorbidity antiphospholipid syndrome (APS). No other autoantibodies investigated were associated with NCF1-339 genotype. Clinical characterization revealed a strong association between NCF1-339 low-ROS genotypes and secondary APS.

Conclusions NCF1-339 genotype affects neutrophil functions of ROS production, NET formation and dependence on mitochondrial ROS. SLE subjects with low-ROS NCF1-339 genotypes are associated with high serum interferon, presence of antiphospholipid antibodies and secondary APS.

Acknowledgements This study was primarily funded by FOREUIM.